Recently, we validated the silencing of BACE1 in wild type and triple transgenic AD mice, where shBACE1miR treatment induced neuroprotection by reduction of CTF (carboxy-terminal fragment) and 1–42 Aβ levels. Here, BACE1 is linked to Alzheimer disease.